Brief: SELLAS Announces Positive Phase 1 Data With CDK9 Inhibitor GFH009 Monotherapy In Patients With Relapsed Hematologic Malignancies
13/12/2022 13:45
Dec 13 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS ANNOUNCES POSITIVE PHASE 1 DATA WITH CDK9 INHIBITOR
GFH009 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY
HEMATOLOGIC MALIGNANCIES
* SELLAS LIFE SCIENCES GROUP INC- ANTICANCER EFFECTS
OBSERVED
ACROSS MULTIPLE DOSE LEVELS IN BOTH ACUTE MYELOID LEUKEMIA AND
LYMPHOMA PATIENTS
Source text for Eikon: ID:nGNXbsXjJ3
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses